CHF 15.5 Million financing round in Swiss Startup Oculis SA
The Tekla Funds (Healthcare, Life Sciences) invested in Oculis SA as part of a CHF 15.5 equity financing round.
Oculis SA is biopharmaceutical Swiss Startup company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases in order to improve the sight and the lives of patients worldwide.
Each Tekla Fund is a non-diversified closed-end fund, the stock of which is traded on the New York Stock Exchange. The Tekla Funds are managed by Tekla Capital Management LLC, a registered investment advisor based in Boston, Massachusetts with approximately USD 3.3 billion of assets under management. They predominately invest in the securities of public and private healthcare companies.
Walder Wyss acted as legal counsel as to Swiss law to the Tekla Funds. The team was led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and further included Marion Bähler (Associate, Corporate/M&A) and Dimitrios Berger (Associate, Corporate/M&A).